[Rapamycin affects eIF- 4E expression in rat myocardial fibroblasts infected by Coxsackievirus B3]

Chun-Yuan Chen1, Yue-Nu Sun, Zuo-Cheng Yang

  • 1Department of Pediatrics, Third Xiangya Hospital, Central South University, Changsha 410013, China. ccyzdh@126.com

Abstract

Insights

Coxsackievirus B3 (CVB3) infection increases eukaryotic initiation factor 4E (eIF-4E) expression in heart cells. Rapamycin treatment inhibits eIF-4E, suggesting its potential for treating viral myocarditis.

Area of Science:

  • Cardiovascular Research
  • Virology
  • Molecular Biology

Context:

  • Viral myocarditis is a serious condition often caused by Coxsackievirus B3 (CVB3).
  • Understanding the molecular mechanisms of CVB3 infection in heart cells is crucial for developing effective treatments.
  • Eukaryotic initiation factor 4E (eIF-4E) plays a key role in protein synthesis and has been implicated in viral pathogenesis.

Purpose:

  • To investigate the effect of rapamycin, an mTOR inhibitor, on eIF-4E expression in CVB3-infected rat myocardial fibroblasts.
  • To determine if rapamycin could be a potential therapeutic agent for viral myocarditis.

Summary:

  • CVB3 infection was confirmed in cultured rat myocardial fibroblasts through mRNA detection and morphological changes.
  • CVB3 infection led to increased eIF-4E expression in myocardial fibroblasts.
  • Rapamycin treatment, alone or in combination with CVB3, significantly reduced eIF-4E expression compared to controls.

Impact:

  • This study identifies a potential drug target (mTOR/eIF-4E pathway) for managing viral myocarditis.
  • Rapamycin demonstrates potential as a therapeutic agent for viral myocarditis by modulating eIF-4E levels.
  • The findings contribute to understanding the pathogenesis of viral myocarditis at a molecular level.